NOT-GM-20-002: Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Program Grant for Multidisciplinary Teams (RM1

Notice of Intent to Publish a Funding Opportunity Announcement for Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional)

Notice Number: NOT-GM-20-002

Key Dates

Release Date: November 18, 2019
Estimated Publication Date of Funding Opportunity Announcement: March 02, 2020
First Estimated Application Due Date: May 25, 2020
Earliest Estimated Award Date: April 01, 2021
Earliest Estimated Start Date: April 01, 2021

Related Announcements
PAR-17-340

Issued by
National Institute of General Medical Sciences (NIGMS)

Purpose

The purpose of this Notice is to inform the biomedical research community that NIGMS is planning to issue a funding opportunity announcement (FOA) to continue the Collaborative Program Grant for Multidisciplinary Teams (RM1) with changes to allow clinical trials.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in winter 2020 with an expected first application due date in spring 2020.

This FOA will utilize the RM1 activity code. Details of the planned FOA are provided below.

Research Initiative Details

The NIGMS Collaborative Program Grant for Multidisciplinary Teams (RM1) is designed to support highly integrated research teams of three to six PD/PIs to address ambitious and challenging research questions that are important for the mission of NIGMS and are beyond the scope of one or two investigators. Collaborative program teams are expected to accomplish goals that require considerable synergy and managed team interactions. Project goals should not be achievable with a collection of individual efforts or projects. Teams are encouraged to consider far-reaching objectives that will produce major advances in their fields.

PAR-17-340 will be reissued to accommodate research that includes mechanistic clinical trials . However, NIGMS does not intend to support FDA-regulated Phase I, II, or III clinical trials through this FOA . The reissued FOA will further clarify that the proposed research program must be central to the NIGMS mission, as well as the availability of developmental funds to support the addition of Early Stage Investigators to the research team.

Funding Information

Estimated Total Funding TBD
Expected Number of Awards 4-6 per year
Estimated Award Ceiling $1,750,000 annual direct costs
Primary CFDA Numbers 93.859

Anticipated Eligible Organizations

Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Regional Organization

Applications are not being solicited at this time.

Inquiries

Please direct all inquiries to:

Peter C. Preusch, Ph.D.
National Institute of General Medical Sciences
301-496-7301
[email protected]